Neurocrine biosciences announces new results from exploratory analyses of the phase 3 cahtalyst™ pediatric study demonstrating crenessity™ reduces glucocorticoid dosing while maintaining or improving androstenedione across patient subgroups

- data consistent across all patient subgroups, including demographic subgroups, by baseline androstenedione levels and by baseline glucocorticoid dose - findings to be presented at the 2025 joint congress of the european society for paediatric endocrinology and the european society of endocrinology san diego , may 8, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced new results from subgroup analyses of the phase 3 cahtalyst™ pediatric study. the analyses showed that, consistently across all of the different subgroups analyzed, pediatric patients with classic congenital adrenal hyperplasia maintained or improved their androstenedione levels with crenessity™ (crinecerfont) while reducing glucocorticoid dosing.
NBIX Ratings Summary
NBIX Quant Ranking